Pharmaceuticals News

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Nu-Tek Secures EcoVadis Supplier Sustainability Rating for 3rd Consecutive Year

Cette distinction d’EcoVadis vient renforcer l’engagement continu de Nu-Tek en faveur de la fabrication durable de nutriments pour milieux de culture cellulaire et d’ingrédients de fermentation sans...

Die erneute Auszeichnung durch EcoVadis bestätigt die kontinuierlichen Investitionen von Nu-Tek in die nachhaltige Herstellung tierfreier Nährstoffe für Zellkulturmedien sowie von Inhaltsstoffen für...

– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in...

TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing...

Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into...

BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory diseaseOn option exercise, Sentynl will have the right to commercialize...

--- A Versatile Complement Therapy Across Ocular, Hematologic, Renal, Dermatological, and Inflammatory Disorders. Key Highlights Commercial Precedent for One Molecule, Two Diseases: Biogen’s $5.6...